Mitochondrial biogenesis and disease
Lead Research Organisation:
Wellcome Trust
Department Name: UNLISTED
Abstract
UK Biobank has been set up to allow the reliable assessment of the relevance of a wide range of different types of exposure (including lifestyle, environment and genes) to a wide range of different diseases (including those that cause much morbidity and disability but have not previously been extensively investigated). Recruitment into UK Biobank started in 2007 (following a successful pilot in 2006), and enrolment of 500,000 men and women aged 40 to 69 was achieved by mid-2010. Such prospective cohorts typically involve collection of either a large amount of data on a small number of participants (sometimes referred to as “data depth”) or a small amount of data on a large number of participants (referred to as “data breadth”). By contrast, in UK Biobank, extensive questionnaire data, physical measures and biological samples have been collected for a very large number of participants (i.e. both depth and breadth have been achieved). This outcome was enabled by the establishment of highly efficient, purpose-designed centralised processes with detailed input from UK Biobank’s extensive academic collaborative network. Activity is now focused on following the health of the participants and providing easy access to researchers who wish to use this resource (which is open for applications from end March 2012 through the website: www.ukbiobank.ac.uk).
In order to enhance further the value of the UK Biobank resource to researchers it is proposed that a wide range of biochemical markers are measured in samples collected at baseline from all 500,000 of the participants. The biomarkers selected for assay have been chosen because they are established risk factors for disease (e.g., lipids for vascular disease, sex hormones for cancer), diagnostic measures (e.g., HbA1c for diabetes and rheumatoid factor for arthritis), markers of exposure (e.g., cotinine for tobacco exposure), or characterize phenotypes not otherwise well assessed (e.g., biomarkers for renal and liver function). UK Biobank’s Enhancements Working Group has been responsible for developing the present proposal following extensive consultation with relevant expert to identify biomarkers that are likely to be of most scientific relevance for studying a wide range of diseases. The availability of this wide range of markers for all of the participants would be a cost-effective way of increasing usability of the resource for many different researchers.
In order to enhance further the value of the UK Biobank resource to researchers it is proposed that a wide range of biochemical markers are measured in samples collected at baseline from all 500,000 of the participants. The biomarkers selected for assay have been chosen because they are established risk factors for disease (e.g., lipids for vascular disease, sex hormones for cancer), diagnostic measures (e.g., HbA1c for diabetes and rheumatoid factor for arthritis), markers of exposure (e.g., cotinine for tobacco exposure), or characterize phenotypes not otherwise well assessed (e.g., biomarkers for renal and liver function). UK Biobank’s Enhancements Working Group has been responsible for developing the present proposal following extensive consultation with relevant expert to identify biomarkers that are likely to be of most scientific relevance for studying a wide range of diseases. The availability of this wide range of markers for all of the participants would be a cost-effective way of increasing usability of the resource for many different researchers.
Technical Summary
UK Biobank has been set up to allow the reliable assessment of the relevance of a wide range of different types of exposure (including lifestyle, environment and genes) to a wide range of different diseases (including those that cause much morbidity and disability but have not previously been extensively investigated). Recruitment into UK Biobank started in 2007 (following a successful pilot in 2006), and enrolment of 500,000 men and women aged 40 to 69 was achieved by mid-2010. Such prospective cohorts typically involve collection of either a large amount of data on a small number of participants (sometimes referred to as “data depth”) or a small amount of data on a large number of participants (referred to as “data breadth”). By contrast, in UK Biobank, extensive questionnaire data, physical measures and biological samples have been collected for a very large number of participants (i.e. both depth and breadth have been achieved). This outcome was enabled by the establishment of highly efficient, purpose-designed centralised processes with detailed input from UK Biobank’s extensive academic collaborative network. Activity is now focused on following the health of the participants and providing easy access to researchers who wish to use this resource (which is open for applications from end March 2012 through the website: www.ukbiobank.ac.uk).
In order to enhance further the value of the UK Biobank resource to researchers it is proposed that a wide range of biochemical markers are measured in samples collected at baseline from all 500,000 of the participants. The biomarkers selected for assay have been chosen because they are established risk factors for disease (e.g., lipids for vascular disease, sex hormones for cancer), diagnostic measures (e.g., HbA1c for diabetes and rheumatoid factor for arthritis), markers of exposure (e.g., cotinine for tobacco exposure), or characterize phenotypes not otherwise well assessed (e.g., biomarkers for renal and liver function). UK Biobank’s Enhancements Working Group has been responsible for developing the present proposal following extensive consultation with relevant expert to identify biomarkers that are likely to be of most scientific relevance for studying a wide range of diseases. The availability of this wide range of markers for all of the participants would be a cost-effective way of increasing usability of the resource for many different researchers.
In order to enhance further the value of the UK Biobank resource to researchers it is proposed that a wide range of biochemical markers are measured in samples collected at baseline from all 500,000 of the participants. The biomarkers selected for assay have been chosen because they are established risk factors for disease (e.g., lipids for vascular disease, sex hormones for cancer), diagnostic measures (e.g., HbA1c for diabetes and rheumatoid factor for arthritis), markers of exposure (e.g., cotinine for tobacco exposure), or characterize phenotypes not otherwise well assessed (e.g., biomarkers for renal and liver function). UK Biobank’s Enhancements Working Group has been responsible for developing the present proposal following extensive consultation with relevant expert to identify biomarkers that are likely to be of most scientific relevance for studying a wide range of diseases. The availability of this wide range of markers for all of the participants would be a cost-effective way of increasing usability of the resource for many different researchers.
Organisations
People |
ORCID iD |
Rory Collins (Principal Investigator) |
Publications
Yang R
(2022)
Importance of healthy lifestyle factors and ideal cardiovascular health metrics for risk of heart failure in Chinese adults.
in International journal of epidemiology
Yang J
(2022)
Coarse Grain Consumption and Risk of Cardiometabolic Diseases: A Prospective Cohort Study of Chinese Adults.
in The Journal of nutrition
Parish S
(2022)
Effects of aspirin on dementia and cognitive function in diabetic patients: the ASCEND trial.
in European heart journal
Nazarzadeh M
(2022)
Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis.
in The lancet. Diabetes & endocrinology
Nag A
(2022)
Human genetics uncovers MAP3K15 as an obesity-independent therapeutic target for diabetes.
in Science advances
Mishra A
(2022)
Stroke genetics informs drug discovery and risk prediction across ancestries.
in Nature
Mentzer AJ
(2022)
Identification of host-pathogen-disease relationships using a scalable multiplex serology platform in UK Biobank.
in Nature communications
Kakkoura MG
(2022)
Dairy consumption and risks of total and site-specific cancers in Chinese adults: an 11-year prospective study of 0.5 million people.
in BMC medicine
Douaud G
(2022)
SARS-CoV-2 is associated with changes in brain structure in UK Biobank.
in Nature